Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease

Next Previous
X
Search
Trial Profile

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO-C3 (Primary)
  • Indications Autoimmune disorders; IgA nephropathy; Kidney disorders; Liver disorders; Membranoproliferative glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Arrowhead Pharmaceuticals

    • Most Recent Events

    • 31 May 2024 According to an Arrowhead Pharmaceutical media release, results assessing the Safety, Tolerability, and Pharmacodynamics of ARO-C3, a Subcutaneously Administered Investigational RNA-interference Therapeutic Targeting Complement C3 in Adult Healthy Volunteers from this trial will be presented at the 22nd Asian Pacific Congress of Nephrology (APCN 2024) - June 13-16, 2024.
    • 11 Apr 2024 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
    • 10 Nov 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top